BioCentury
ARTICLE | Company News

Aestus Therapeutics, Astellas deal

July 5, 2010 7:00 AM UTC

Astellas granted Aestus an exclusive, worldwide license to FK614. Aestus, which renamed the compound ATx08-001, plans to start a Phase II trial of the peroxisome proliferation activated receptor (P...